Advances in Intensive Care Medicine

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 176

Special Issue Editor

Special Issue Information

Dear Colleagues,

This Special Issue on "Advances in Intensive Care Medicine" offers an in-depth exploration of the latest developments and research that are transforming the field of critical care. It highlights significant advancements in patient management and technological innovations that enhance treatment outcomes in intensive care units (ICUs).

Key discussions center around the integration of artificial intelligence and machine learning in monitoring respiratory status and facilitating timely interventions, thereby improving patient safety. This Special Issue emphasizes the importance of personalized medicine, showcasing how genetic and biomarker research can inform targeted therapies for conditions such as acute respiratory distress syndrome (ARDS). All types of papers are welcomed, including review articles, original research, point-of-views, and others.

This Special Issue serves as a vital resource for clinicians, researchers, and healthcare policymakers, providing crucial insights into the evolving landscape of critical care medicine and its implications for future practice.

Dr. Denise Battaglini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • machine learning
  • critical care
  • intensive care
  • ARDS
  • mechanical ventilation
  • personalized medicine
  • advances

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1108 KiB  
Article
The ADVanced Organ Support (ADVOS) Hemodialysis System in Postoperative Cardiogenic Shock and Multiple Organ Failure: First Results in Cardiac Surgery Patients
by Veronika Walter, Ekaterina Hinrichs, Tarek Alloush, Aritz Perez Ruiz de Garibay, Gregor Warnecke, Wiebke Sommer, Hanna Gravert, Christina Grothusen, Janine Becker, Alexander Thiem and Bernd Panholzer
Life 2025, 15(7), 1042; https://doi.org/10.3390/life15071042 - 30 Jun 2025
Abstract
Background: The management of multiple organ failure in the vulnerable cohort of cardiac surgery patients with cardiogenic shock remains a significant challenge, often impairing patient survival. A multimodal approach at targeting organ dysfunction seems to be a promising strategy, encompassing both hemodynamic support [...] Read more.
Background: The management of multiple organ failure in the vulnerable cohort of cardiac surgery patients with cardiogenic shock remains a significant challenge, often impairing patient survival. A multimodal approach at targeting organ dysfunction seems to be a promising strategy, encompassing both hemodynamic support as well as differentiated organ replacement therapy. Materials and Methods: In our retrospective study we examined the impact of the ADVOS (advanced organ support) system on overall outcomes and survival in an all-comers group of 22 cardiac surgery patients with postoperative cardiogenic shock and multiple organ failure. Aims: The objective of the study was to assess the feasibility and potential benefits of ADVOS treatment in this patient population. Results: The standard care management in combination with ADVOS therapy corrected acid–base balance (pH 7.33 vs. 7.44, p = 0.001; base excess −3.2 vs. 2.4 mmol/L, p < 0.001). This contributed to restoring hemodynamic balance after two consecutive ADVOS treatments (vasoactive inotropic score (VIS) 59 vs. 21, p = 0.007, noradrenaline 0.470 vs. 0.180 µg/kg/min, p = 0.009). Conclusions: Our findings indicate that ADVOS treatment is both feasible and safe, with a substantial proportion of patients demonstrating improvements in organ function and overall outcomes. Full article
(This article belongs to the Special Issue Advances in Intensive Care Medicine)
Show Figures

Figure 1

Back to TopTop